대한뉴팜

Daehan Nupharm recorded first-quarter sales of 51.5 billion KRW in 2023, marking a 13% increase compared with the same period of the previous year. Operating profit rose 10.6% year-on-year to 5.5 billion KRW.Each business division is strengthening its research and development activities and reflecting the results in performance. The company’s Industry–Academia–Research Center, located in the 2nd Pangyo Techno Valley, is focusing on the development of improved drugs and biopharmaceuticals. In addition, Daehan Nupharm has newly established the Future Business Division to create synergy among its human pharmaceuticals, veterinary medicines, and bio businesses.To diversify its distribution channels, the company launched several specialized brands: a general health supplement brand, an exclusive brand for veterinary hospitals, and a healthcare brand for clinics. DiNU is a health supplement line sold through online channels, with its dual-capsule probiotic product Pharaotics contributing significantly to sales growth. The veterinary hospital brand DiAnge was launched to develop and supply products “for veterinarians who protect the pets that are angels to their owners.” The new clinic-exclusive brand Dr. DiNU, launched in January, is expanding its product lineup of health supplements available only through medical institutions.Since late last year, Daehan Nupharm has been expanding its vaccine distribution business. In November, the company began sales of Korea’s only pit viper antivenom, followed by the launch of the nation’s first varicella vaccine in December. Starting this month, the company has also begun distribution of a Japanese encephalitis live vaccine, establishing a new revenue stream through vaccine sales.The company is also focusing on R&D for geriatric diseases and continues to release new respiratory, antibiotic, and cardiovascular drugs, which are contributing to revenue growth. In June, Daehan Nupharm plans to launch Newtomega Soft Capsules, a combination drug containing atorvastatin and omega-3 acid ethyl esters, which is expected to further drive sales growth.

This is a professional guide and checklist for the treatment using psychotropic appetite suppressant drugs. Our relevant products: 1) Pentine Tablet (Phendimetrazine 35mg)2) PTM Tablet (Phentermine Hydrochloride 18.75mg)3) Festin Tablet (Phentermine Hydrochloride 37.5mg) Please refer to the attached file for detailed information.

Unlike the health supplements sold through the existing 'DiNU' online mall, Dr. DiNU products are exclusively available for purchase in medical institutions. Initially, two products were released: 'Dr. DiNU Super Arginine Powder 6000' and 'Dr. DiNU Glutamine Powder 6000'. Another product, 'Dr. DiNU Immune Alpha Capsule', is scheduled for release in February. 'Dr. DiNU Super Arginine Powder 6000' contains a high dose of 6000 mg of arginine, aimed at restoring lost vitality in people fatigued by modern life. It comes in a convenient jelly stick form with a natural grape flavor, noted for its excellent sweetness. It also contains four kinds of vitamins, nine amino acids, and fermented mugwort extract powder to support additional nutritional balance. 'Dr. DiNU Glutamine Powder 6000' was launched to promote balanced health through amino acid nutrition. It contains 6000 mg of glutamine to support gut health and includes peach concentrate for sweetness. Additional nutrients include 1000 mg arginine, vitamin A, zinc, and hydrolyzed milk protein, ensuring all essential nutrients are covered. Daehan Nupharm is a company strong in the obesity and well-being pharmaceutical markets. Leveraging this strength, the company plans to release products in the food market that enhance immunity and help overcome nutritional imbalances that may occur during dieting. The goal is to expand the 'Dr. DiNU' section within hospitals to increase presence and accessibility.

Wonsuk Lee was inaugurated as CEO and President of Daehan Nupharm on January 2. Born in 1977, he joined the company in 2004, progressing through roles in the overseas business team, finance team, and management team, and most recently served as Vice President of the Management Headquarters. At the inauguration ceremony held together with the 2023 kick-off meeting, he was awarded the Long-term Service Award and the Daehan Nupharm Person of the Year Award. In his inaugural speech, he outlined future management policies centered on the keywords “listening,” “action,” and “responsibility.” Daehan Nupharm is a pharmaceutical and veterinary medicine manufacturer and distributor focused on developing biopharmaceuticals and improved new drugs. The company plans to launch a variety of pharmaceuticals and health supplements, including ‘Zero-Be’ tablets that improve dosing convenience and ‘Cambel Double’ tablets, which are twice the dosage of the 'Cambel' herbal formula. The company has also been preparing for pet product development for several years and aims to release eight items this year. It is strengthening R&D for new drug development, having completed the Industry-Academia-Research Center in the Second Pangyo Techno Valley in 2021. The center is designed to improve work efficiency and welfare through the keywords “research and development” and “communication.” In his speech, Lee emphasized creating synergies between the human pharmaceuticals, veterinary medicines, and health supplements divisions by newly establishing a Future Business Division and strengthening pipelines across divisions. He expressed his commitment to building a workplace where employees are proud to belong to Daehan Nupharm and rewarded for their achievements as the company grows into a global pharmaceutical and bio company.

Daehan Nupharm reported third-quarter sales of approximately 147.9 billion KRW, an 18% increase compared to the same period last year, with an operating profit of 21.2 billion KRW (operating margin of 14.3%). Additionally, the company posted a net profit of 20.8 billion KRW, up 48% year-on-year, boosted by an 8.9 billion KRW income from winning a lawsuit. The company continues to grow by focusing on improved new drugs, biopharmaceutical development, and veterinary medicines. They plan to launch various pharmaceuticals, health supplements, and animal drugs from the fourth quarter through early next year. First, the recent launch of the DPP-4 inhibitor for type 2 diabetes patients, including the single-agent 'Teneltin tablet' and the combination drug 'Tenelpomin extended-release tablet', provides new momentum, offering benefits like no risk of hypoglycemia or weight gain and suitability irrespective of kidney function. Second, enhanced-compliance drugs 'Zero-Be tablet' and 'Cambel Double tablet', which doubles the dosage of the 'Cambel tablet' herbal formula, are expected to be launched in February 2023, improving stability and dosing convenience. Third, the hospital-exclusive health supplement brand 'Dr. DiNU' will launch in November with four new products including high-purity phosphatidylcholine, Super Arginine 5000, Glutamine 6000, and Immune Alpha Capsule, expanding the health supplement sales channel. Fourth, Daehan Nupharm is expanding its pet products with the upcoming Q4 launch of 'RS-Pro', a natural ingredient-based supplement improving skin and hair conditions, showing effects on promoting hair growth and alleviating skin issues without steroids. These initiatives underscore Daehan Nupharm's sustained growth strategy through diverse product innovation across pharmaceuticals, supplements, and veterinary care.

Daehan Nupharm achieved sustained growth with second-quarter sales of 96.2 billion KRW, marking a 15% increase year-over-year.Operating profit reached 12.7 billion KRW, and net profit climbed to 14.9 billion KRW, boosted by an 8.9 billion KRW gain related to a lawsuit victory.The operating margin was 13%. The company plans to continue expanding with new product launches across pharmaceutical, health supplement, and veterinary medicine divisions. Notably, the pet product brand 'DiAnge' is set to aggressively expand sales activities following its launch in May.New products for animal health and stress relief are also planned for release in the second half of the year.

Daehan Nupharm launched the pet hospital-exclusive brand 'DiAnge', releasing its first product, a multi-strain probiotic called 'UD Pro'. The brand name combines Daehan Nupharm's initial ‘D’ with the French word 'Ange' meaning ‘angel,’ symbolizing products developed and supplied for “pets, who are angels to their owners,” and for veterinarians, the “guardian angels” of these pets. The first product, UD Pro, contains five probiotic strains including Lactobacillus crispatus and demonstrated kidney disease improvement effects in an eight-week feeding trial with pets suffering from renal disease. Blood serum chemistry tests showed decreases in BUN, creatinine, and B/C ratio, along with overall improvements in fur condition and behavior. UD Pro’s probiotics,ed by the Ministry of Agriculture, Food and Rural Affairs-certified institution for acid resistance, bile tolerance, and intestinal adhesion capability, are manufactured with a special method maintaining long-term stability in liquid refrigerated form. The liquid product is conveniently administered by adding 3–8s to food or treats, enhancing ease of administration compared to powder or capsule forms. Daehan Nupharm is also strengthening veterinary pharmaceutical pipelines, planning sequential launches within the year of antiemetics, heartworm preventatives, antifungals, NSAID drugs for pets, and pancreatic function enhancers. This evidences Daehan Nupharm’s holistic growth in pet health through specialized nutrition and pharmaceutical solutions.

Daehan Nupharm achieved sales of 45.6 billion KRW in the first quarter of 2022, representing a 16% increase compared to the same period of the previous year. Operating profit rose 7.6% to 7.1 billion KRW, and net profit reached 11.6 billion KRW, a 191% increase year-on-year, driven by a favorable final ruling in a lawsuit resulting in the reversal of approximately 9 billion KRW in litigation reserves. The human pharmaceuticals division showed strong growth due to increased sales of antibiotics and respiratory disease treatments amid the spread of the Omicron variant, as well as growth in the company's core injectable products. Sales of obesity-related products are rising with the approach of the summer season, supporting expectations of continued growth in the second half. The animal health division launched the antibiotic tulathromycin and plans to introduce hormone products for pigs, stress relief agents 'Pamdi Zero', and aquatic stress relievers 'Aqua Luthione' in the second half. The company is actively advancing both industrial and companion animal businesses. Overseas exports are growing with increasing demand for the company's freeze-dried injectable product 'Liporase' beyond Southeast Asia into Latin America and the Middle East. Registrations in Iran and Peru have been recently completed, with the first shipments in March encouraging export growth. Daehan Nupharm reports balanced growth across all divisions, expecting further expansion through rising overseas demand for injectable products and global market development.

Daehan Nupharm unveiled its new Corporate Identity (CI). The new symbol represents the company’s initial ‘D’ as a cell, the basic unit of life, extending outward. The English name was changed from New Pharm to Nupharm, creating a single word without changing pronunciation. Founded in 1984, Daehan Nupharm started with animal feed additives and has grown into a mid-sized pharmaceutical and bio company listed on KOSDAQ, operating in human pharmaceuticals, veterinary medicines, biopharmaceuticals, medical devices, and health supplements. The company has maintained an average annual growth rate of 15% over the past decade, reaching sales of 166.5 billion KRW in 2021 and consistently exceeding 10 billion KRW in exports since receiving the ‘Ten Million Dollar Export Tower’ award in 2015. To enhance research capabilities and improve work environments, Daehan Nupharm completed its Industry-Academia-Research Center in the 2nd Pangyo Techno Valley and relocated its Hwaseong Central Research Institute and Osong Bio Research Institute to Pangyo, fostering synergy across divisions. The company is also constructing a new research building at its headquarters in the Hyangnam Pharmaceutical Industrial Complex this year. Alongside the new CI, Daehan Nupharm launched the campaign, sharing a vision to grow together with employees and become a global pharmaceutical and bio company that spreads warmth. The focus is on discovering future growth engines and enhancing core competencies in each division to ensure sustainable growth.